Casein kinase 1α-dependent feedback loop controls autophagy in RAS-driven cancers

Journal of Clinical Investigation

Volumn 125, Issue 4, 2015, Pages 1401-1418

  Cheong, Jit Kong ^a   Zhang, Fuquan ^a   Chua, Pei Jou ^b   Bay, Boon Huat ^b   Thorburn, Andrew ^c   Virshup, David M ^a,b,d  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE IALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MICROTUBULE ASSOCIATED PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; TRANSCRIPTION FACTOR FKHRL1; AKT1 PROTEIN, HUMAN; CASEIN KINASE I; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PROTEIN P21; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CANCER CELL LINE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE CANCER; NEGATIVE FEEDBACK; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; COMPARATIVE STUDY; ENZYMOLOGY; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NEOPLASM; NUDE MOUSE; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; TRANSCRIPTION INITIATION;

AMINO ACID SEQUENCE; ANIMALS; AUTOPHAGY; CASEIN KINASE I; FEEDBACK, PHYSIOLOGICAL; FIBROBLASTS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS; ONCOGENE PROTEIN P21(RAS); PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; TOR SERINE-THREONINE KINASES; TRANSCRIPTIONAL ACTIVATION;

EID: 84926374854     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78018     Document Type: Article

References (67)

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012;13(8):790-801.
2. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22.
3. Elgendy M, Sheridan C, Brumatti G, Martin SJ. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol Cell. 2011;42(1):23-35.
4. Guo JY, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011;25(5):460-470.
5. Kim MJ, et al. Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation. J Biol Chem. 2011;286(15):12924-12932.
6. Lock R, et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell. 2011;22(2):165-178.
7. Yang S, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011;25(7):717-729.
8. Slattum G, Gu Y, Sabbadini R, Rosenblatt J. Autophagy in oncogenic K-Ras promotes basal extrusion of epithelial cells by degrading S1P. Curr Biol. 2014;24(1):19-28.
9. Guo JY, et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 2013;27(13):1447-1461.
10. Lock R, Kenific CM, Leidal AM, Salas E, Debnath J. Autophagy-dependent production of secreted factors facilitates oncogenic RAS-driven invasion. Cancer Discov. 2014;4(4):466-479.
11. Gump JM, Thorburn A. Autophagy and apoptosis: what is the connection? Trends Cell Biol. 2011;21(7):387-392.
12. Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy. 2014;10(8):1415-1425.
13. Mahalingam D, et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy. 2014;10(8):1403-1414.
14. Rangwala R, et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy. 2014;10(8):1391-1402.
15. Rangwala R, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 2014;10(8):1369-1379.
16. Rosenfeld MR, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 2014;10(8):1359-1368.
17. Vogl DT, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy. 2014;10(8):1380-1390.
18. Morgan MJ, et al. Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent. Autophagy. 2014;10(10):1814-1826.
19. Cheong JK, et al. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1d/e and Wnt/β-catenin independent inhibition of mitotic spindle formation. Oncogene. 2011;30(22):2558-2569.
20. Szyniarowski P, et al. A comprehensive siRNA screen for kinases that suppress macroautophagy in optimal growth conditions. Autophagy. 2011;7(8):892-903.
21. Cheong JK, Virshup DM. Casein kinase 1: complexity in the family. Int J Biochem Cell Biol. 2011;43(4):465-469.
22. Davidson G, et al. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature. 2005;438(7069):867-872.
23. Firestein R, et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008;455(7212):547-551.
24. Gallego M, Virshup DM. Post-translational modifications regulate the ticking of the circadian clock. Nat Rev Mol Cell Biol. 2007;8(2):139-148.
25. Knippschild U, Gocht A, Wolff S, Huber N, Lohler J, Stoter M. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal. 2005;17(6):675-689.
26. Price MA. CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling. Genes Dev. 2006;20(4):399-410.
27. Liu C, et al. Control of β-catenin phosphorylation/ degradation by a dual-kinase mechanism. Cell. 2002;108(6):837-847.
28. Huart AS, MacLaine NJ, Meek DW, Hupp TR. CK1a plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem. 2009;284(47):32384-32394.
29. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature. 1999;400(6743):464-468.
30. Scherz-Shouval R, Weidberg H, Gonen C, Wilder S, Elazar Z, Oren M. p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation. Proc Natl Acad Sci U S A. 2010;107(43):18511-18516.
31. Jaras M, et al. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014;211(4):605-612.
32. Rena G, Bain J, Elliott M, Cohen P. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 2004;5(1):60-65.
33. Denoyelle C, et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol. 2006;8(10):1053-1063.
34. Milani M, et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res. 2009;69(10):4415-4423.
35. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science. 1993;260(5104):85-88.
36. Cruciat CM, et al. RNA helicase DDX3 is a regulatory subunit of casein kinase 1 in Wnt-beta-catenin signaling. Science. 2013;339(6126):1436-1441.
37. Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8(4):445-544.
38. Mammucari C, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 2007;6(6):458-471.
39. Webb AE, Brunet A. FOXO transcription factors: key regulators of cellular quality control. Trends Biochem Sci. 2014;39(4):159-169.
40. Zhao J, et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007;6(6):472-483.
41. Fullgrabe J, Klionsky DJ, Joseph B. The return of the nucleus: transcriptional and epigenetic control of autophagy. Nat Rev Mol Cell Biol. 2014;15(1):65-74.
42. Flotow H, Graves PR, Wang AQ, Fiol CJ, Roeske RW, Roach PJ. Phosphate groups as substrate determinants for casein kinase I action. J Biol Chem. 1990;265(24):14264-14269.
43. Thorne CA, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1a. Nat Chem Biol. 2010;6(11):829-836.
44. Swiatek W, et al. Regulation of casein kinase I epsilon activity by Wnt signaling. J Biol Chem. 2004;279(13):13011-13017.
45. Lee JC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372(6508):739-746.
46. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2002; 1(12):989-997.
47. Favata MF, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998;273(29):18623-18632.
48. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
49. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011; 147(4):728-741.
50. Karsli-Uzunbas G, et al. Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov. 2014;4(8):914-927.
51. Hu Y, Song W, Cirstea D, Lu D, Munshi NC, Anderson KC. CSNK1a1 mediates malignant plasma cell survival. Leukemia. 2015;29(2):474-482.
52. Omerovic J, Hammond DE, Clague MJ, Prior IA. Ras isoform abundance and signalling in human cancer cell lines. Oncogene. 2008; 27(19):2754-2762.
53. Zhang P, et al. MiR-155 is a liposarcoma oncogene that targets casein kinase-1a and enhances β-catenin signaling. Cancer Res. 2012;72(7):1751-1762.
54. Hariharan N, Maejima Y, Nakae J, Paik J, Depinho RA, Sadoshima J. Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ Res. 2010;107(12):1470-1482.
55. Liu HY, et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem. 2009;284(45):31484-31492.
56. Sengupta A, Molkentin JD, Yutzey KE. FoxO transcription factors promote autophagy in cardiomyocytes. J Biol Chem. 2009;284(41):28319-28331.
57. Zhao Y, et al. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol. 2010;12(7):665-675.
58. Chen L, Li C, Pan Y, Chen J. Regulation of p53-MDMX interaction by casein kinase 1 a. Mol Cell Biol. 2005;25(15):6509-6520.
59. Rivers A, Gietzen KF, Vielhaber E, Virshup DM. Regulation of casein kinase I e and casein kinase I by an in vivo futile phosphorylation cycle. J Biol Chem. 1998;273(26):15980-15984.
60. Brunet A, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857-868.
61. Bidere N, et al. Casein kinase 1alpha governs antigen-receptor-induced NF-κB activation and human lymphoma cell survival. Nature. 2009;458(7234):92-96.
62. Voorhoeve PM, Agami R. The tumor-suppressive functions of the human INK4A locus. Cancer Cell. 2003;4(4):311-319.
63. Bunz F, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999;104(3):263-269.
64. McCright B, Virshup DM. Identification of a new family of protein phosphatase 2A regulatory subunits. J Biol Chem. 1995;270(44):26123-26128.
65. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1(3):1458-1461.
66. Nakayama GR, Caton MC, Nova MP, Parandoosh Z. Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J Immunol Methods. 1997;204(2):205-208.
67. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24(3):148-154.